South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.
South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience has broken ground on an approximately 4,200 m2 expansion of its L House vaccine manufacturing facility in Andong, Gyeongsangbuk-do, South Korea, which will serve as the production base for pneumococcal conjugate vaccine candidate GBP410, jointly developed by SK Bioscience and Sanofi, who are co-investing in the expansion.
South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience wants to expand its vaccine manufacturing plant located in Andong, South Korea to approximately 4,200 m2 through joint investment with Sanofi.
South Korea-based CDMO SK Bioscience, with cash in hand from an initial public offering, has announced plans to pour 150 billion won ($132 million) into vaccine production up to 2024, which will mean to adding some 99,130 m2 of production space and equipping its plant at Andong to make newer mRNA- and viral vector-based Covid-19 vaccines.
